Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Glasdegib (Daurismo) is indicated for the treatment of newly-diagnosed acute myeloid leukemia in combination with low-dose cytarabine, specifically targeting patients aged 75 years or older or those with comorbidities that prevent the use of intensive induction chemotherapy.
• Three studies were reviewed to gather information about this drug. These studies provided insights into various treatments for acute myeloid leukemia, focusing on populations similar to those targeted by Daurismo.
• The effectiveness and safety profiles of different therapies varied significantly. Targeted therapies combined with hypomethylating agents showed better overall survival rates but also had more adverse events compared to control groups.
• Hypomethylating agent and TKI combinations demonstrated promising results comparable to intensive chemotherapy combined with TKIs; however, specific data regarding their safety profile was not available.
• For older and medically unfit patients unsuitable for standard induction therapy, outcomes using hypomethylating agents or low-dose cytarabine showed moderate effectiveness but high mortality at 60 days (21%).
• While glasdegib's incorporation into new AML drugs was highlighted in one study discussing CML-MBP management parallels due to its clinical resemblance to AML, direct comparative efficacy and safety data between glasdegib and other agents were lacking across all three studies reviewed.